

2024 Medicare Part D Formulary Change

We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy restrictions on a drug (or move a drug to a higher cost-sharing tier), we will let you know of the change. However, if the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and let you know.

The product changes noted below will be implemented on the Medicare Part D Plan formulary.

To see if your drug is on this list, scroll down or click this [SEARCH] button and enter the name of your drug in the pop-up task pane.

New Added Products: Effective 4/1/2024

Drug	Restrictions*
BOSULIF 100 MG CAPSULE	PA QL
BOSULIF 50 MG CAPSULE	PA QL
BROMFENAC 0.07 % EYE DROPS	
GABAPENTIN ER 300 MG TABLET,EXTENDED RELEASE 24 HR	PA QL
GABAPENTIN ER 600 MG TABLET,EXTENDED RELEASE 24 HR	PA QL
INPEFA 400 MG TABLET	PA QL
IWILFIN 192 MG TABLET	PA QL LA
LIDOCAN III 5 % TOPICAL PATCH	PA QL
PENBRAYA (PF) 5 MCG-120 MCG/0.5 ML INTRAMUSCULAR KIT	
RISPERIDONE MICROSPHERES ER 12.5 MG/2 ML INTRAMUSCULAR SUSP,EXT RELEAS	QL
RISPERIDONE MICROSPHERES ER 25 MG/2 ML INTRAMUSCULAR SUSP,EXT RELEASE	QL
RISPERIDONE MICROSPHERES ER 37.5 MG/2 ML INTRAMUSCULAR SUSP,EXT RELEAS	QL
RISPERIDONE MICROSPHERES ER 50 MG/2 ML INTRAMUSCULAR SUSP,EXT RELEASE	QL



Drug	Restrictions*
SODIUM,POTASSIUM,MAG SULFATES 17.5 GRAM-3.13 GRAM-1.6 GRAM ORAL SOLN	
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE	QL
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE	QL
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE	QL
SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE	QL
XALKORI 150 MG ORAL PELLETS	PA QL
XALKORI 20 MG ORAL PELLETS	PA QL
XALKORI 50 MG ORAL PELLETS	PA QL

New Added Products: Effective 3/1/2024

Drug	Restrictions*
AKEEGA 100 MG-500 MG TABLET	PA QL LA
AKEEGA 50 MG-500 MG TABLET	PA QL LA
AUGTYRO 40 MG CAPSULE	PA QL
KALYDECO 5.8 MG ORAL GRANULES IN PACKET	PA QL
KESIMPTA PEN 20 MG/0.4 ML SUBCUTANEOUS PEN INJECTOR	PA QL
VIGPODER 500 MG ORAL POWDER PACKET	PA LA
ZENPEP 60,000-189,600-252,600 UNIT CAPSULE,DELAYED RELEASE	

New Added Products: Effective 2/1/2024

Drug	Restrictions*
ADALIMUMAB-ADBM 10 MG/0.2 ML SUBCUTANEOUS SYRINGE KIT	PA QL
ADALIMUMAB-ADBM 20 MG/0.4 ML SUBCUTANEOUS SYRINGE KIT	PA QL
ADALIMUMAB-ADBM 40 MG/0.8 ML SUBCUTANEOUS PEN KIT	PA QL



IMUMAB-ADBM 40 MG/0.8 ML SUBCUTANEOUS GE KIT IMUMAB-ADBM(CF) PEN CROHN'S-UC-HS FER 40 MG/0.8 ML SUBCUT KIT IMUMAB-ADBM(CF) PEN PSORIASIS-UVEITIS 40 MG/0.8 ML SUBCUT KIT ELLIPTA 50 MCG-25 MCG/DOSE POWDER FOR ATION NA 160 MCG-4.5 MCG/ACTUATION HFA SOL INHALER NA 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QL AQLA 5 MG CAPSULE PA QL	Restrictions*
IMUMAB-ADBM(CF) PEN CROHN'S-UC-HS FER 40 MG/0.8 ML SUBCUT KIT IMUMAB-ADBM(CF) PEN PSORIASIS-UVEITIS 40 MG/0.8 ML SUBCUT KIT ELLIPTA 50 MCG-25 MCG/DOSE POWDER FOR ATION NA 160 MCG-4.5 MCG/ACTUATION HFA SOL INHALER NA 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QL	,
PA QUI IMUMAB-ADBM(CF) PEN PSORIASIS-UVEITIS 40 MG/0.8 ML SUBCUT KIT ELLIPTA 50 MCG-25 MCG/DOSE POWDER FOR QL ATION NA 160 MCG-4.5 MCG/ACTUATION HFA SOL INHALER NA 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QUI P	L
40 MG/0.8 ML SUBCUT KIT ELLIPTA 50 MCG-25 MCG/DOSE POWDER FOR QL ATION NA 160 MCG-4.5 MCG/ACTUATION HFA SOL INHALER NA 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QL	L
LATION NA 160 MCG-4.5 MCG/ACTUATION HFA SOL INHALER NA 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QL	L
SOL INHALER NA 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QL	
LER ONIDINE 0.1 % EYE DROPS EMBA 74.5 MG CAPSULE AQLA 1 MG CAPSULE PA QL	
EMBA 74.5 MG CAPSULE PA AQLA 1 MG CAPSULE PA QL	
AQLA 1 MG CAPSULE PA QL	
<u> </u>	
AOLA 5 MG CARSIILE	L
AQLA J IVIO CAPSULE PA QL	L
MOZ(CF) PEDIATRIC CROHN'S STARTR 80 MG/0.8 PA QUI	L
A 200 MG TABLET PA QU	L
ZEQ 0.1 % DENTAL PASTE	
VRIO 200 MG CAPSULE (EUA)	
JM CITRATE 8 MEQ/5 ML ORAL SOLUTION	
RA 100 MG TABLET PA QU	L
RA 150 MG TABLET PA QU	L
RA 200 MG TABLET PA QU	L
OVID 150 MG-100 MG TABLETS IN A DOSE PACK AL DOSE)	
OVID 300 MG (150 MG X 2)-100 MG TABLETS IN QL	
PANIB 200 MG TABLET PA QU	L
ASTATIN CALCIUM 1 MG TABLET QL	
ASTATIN CALCIUM 2 MG TABLET QL	
ASTATIN CALCIUM 4 MG TABLET QL	
GLIPTIN 2.5 MG TABLET QL	
GLIPTIN 2.5 MG-METFORMIN ER 1,000 MG ET,EXTEND RELEASE 24HR MP	
GLIPTIN 5 MG TABLET QL	



Drug	Restrictions*
SAXAGLIPTIN 5 MG-METFORMIN ER 1,000 MG TABLET,EXTEND RELEASE 24HR MP	QL
SAXAGLIPTIN 5 MG-METFORMIN ER 500 MG TABLET,EXTEND RELEASE 24HR MP	QL
TESTOSTERONE 12.5 MG/1.25 GRAM PER PUMP ACTUATION (1%) TRANSDERMAL GEL	PA QL
TRUQAP 160 MG TABLET	PA QL
TRUQAP 200 MG TABLET	PA QL
TURQOZ (28) 0.3 MG-30 MCG TABLET	
VANFLYTA 17.7 MG TABLET	PA QL
VANFLYTA 26.5 MG TABLET	PA QL
XDEMVY 0.25 % EYE DROPS	PA QL
ZURZUVAE 20 MG CAPSULE	PA
ZURZUVAE 25 MG CAPSULE	PA
ZURZUVAE 30 MG CAPSULE	PA



For more information about how these changes may affect your cost-sharing, such as copayments or coinsurance, or for more information about asking for an updated coverage determination or a formulary exception, please see the plan Evidence of Coverage.

Alternative drugs are drugs in the same therapeutic category/class as the affected drug. Only your doctor can determine alternative drugs that are appropriate for you given the individualized nature of drug therapy. Please talk to your doctor about any changes or recommendations to your medical care and prescription drug therapy. Alternative drugs and additional information about formulary changes can be found on the plan formulary,

*Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist.

[LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy

ConnectiCare, Inc. is an HMO-POS plan with a Medicare contract. ConnectiCare Insurance Company, Inc. is an HMO-POS D-SNP plan with a Medicare contract and a contract with the Connecticut Medicaid Program. Enrollment in a ConnectiCare Medicare plan depends on contract renewal.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2025.

This document includes ConnectiCare Medicare Plan's partial formulary as of April 1, 2024. For a complete, updated formulary, please visit our website at www.connecticare.com/Medicare or call the Member Services number below.

For alternative formats or language, please call Member Services toll free at: ConnectiCare's Member Services at 800-224-2273. From Oct. 1 through March 31: 8 a.m. to 8 p.m., seven days a week. From April 1 through Sept. 30: 8 a.m. to 8 p.m., Monday through Saturday.

TTY users should call 711.

24238v11